Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center

home / authors / francis-paul-worden-md-university-of-michigan-comprehensive-cancer-center

Articles

Sequencing Throughout Multiple Lines of Therapy in RR DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

June 5th 2023

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Optimizing Use of RET Inhibitors in Patients With RR DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 29th 2023

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 3: Treating RR DTC With an Identified RET Fusion

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 29th 2023

Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.

Practical Considerations for Utilizing Second-Line Therapy in RR DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 22nd 2023

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

Clinical Data Behind Second-Line Therapy in RR DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 22nd 2023

A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 2: Second-Line Management of RR DTC With Cabozantinib

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 15th 2023

Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.

RR DTC: Managing Adverse Events With Dose Reductions or Holds

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 15th 2023

Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.

Quality of Life and Real-World Data in Patients With RR DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 8th 2023

Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.

Overview of Available Treatment Options for RR DTC

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 8th 2023

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

RR DTC: Active Surveillance vs Initiating Systemic Therapy

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 1st 2023

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

Defining Radioiodine-Refractory Differentiated Thyroid Cancer

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

May 1st 2023

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

Practical Considerations for Managing RR DTC With Systemic Therapy

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

April 24th 2023

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

Lori J. Wirth, MD, Massachusetts General Hospital;Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego;Francis Paul Worden, MD, University of Michigan Comprehensive Cancer Center;Marcia S. Brose, MD, PhD

April 24th 2023

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.